News
GAVI launches COVID-19 Global Vaccine Access Facility
Het wereldwijde vaccinatieprogramma GAVI lanceerde vrijdag het COVID-19 Global Vaccine Access Facility (COVAX). Landen die hieraan deelnemen, zeggen vooraf toe een aantal doses vaccin te kopen, en hebben daarmee gegarandeerd toegang tot vaccinatie.
AbbVie Works with Dutch Partners to Develop Corona Medicine
AbbVie is een samenwerking aangegaan met de Universiteit Utrecht, de Erasmus Universiteit en het Rotterdamse bedrijf Harbour BioMed voor de ontwikkeling van een monoklonale antilichaamtherapie gericht op het voorkomen en behandelen van COVID-19.
Utrecht University Launches ‘Mission-oriented Innovation Policy Observatory’
Amongst policy makers across the world, there is a widespread interest in using ambitious missions like ‘an entirely carbon-free electricity system by 2050’ to boost innovation and tackle complex societal challenges. Possibilities to do so, however, are hampered by unresolved questions and largely neglected tensions. Researchers from Utrecht University have now launched an initiative for identifying, studying and overcoming such issues.
Cooperation Germany, France, Italy and the Netherlands in Acquiring Vaccines for European and Other Countries
Duitsland, Frankrijk, Italië en Nederland bundelen de krachten in de onderhandeling met ontwikkelaars en producenten van potentiële coronavaccins. De vier landen verkennen gezamenlijk diverse kansrijke initiatieven en zijn in gesprek met verschillende farmaceutische bedrijven. Het is de bedoeling de productie van vaccins waar mogelijk op Europese bodem plaats te laten vinden.
Four More Projects Awarded in COVID-19 Call
At the end of March, Health~Holland set up a call for COVID-19 related research proposals. In May we announced that in only one month four projects were awarded by the Health~Holland board. One week later, three more projects were awarded. Now, more good news is to follow; four more projects have been awarded and granted PPP Allowance to start their research.
Intravacc and EpiVax Team Up in Development of COVID-19 Emerging Vaccine
Intravacc, one of the world’s leading translational research and development vaccine institutes and EpiVax, a biotechnology company, announce that they have entered into a collaboration agreement to further progress an novel vaccine against COVID-19, based on Intravacc’s proprietary Outer Membrane Vesicles (OMV) technology platform.
Key Stakeholders from Massachusetts and The Netherlands Discuss Lessons Learned from COVID-19
On Monday the 8th of June, key stakeholders from Massachusetts and the Netherlands will come together in a virtual session to discuss about the developments in both life sciences ecosystems in the light of the COVID-19 pandemic outbreak, and how international collaboration, now and in the future, could contribute to solutions.
New IMDI Newsletter Is Out Now
The new IMDI newsletter, June edition is out now. Read the publication of IMDI results of projects that received funding in 2014 and more!
Mymetics Reports Successful Preclinical Study Results with Cop-Virosomes as Second-Generation Allergy Immunotherapy
Mymetics Corporation announced that Stallergenes Greer and Anergis, reported the results of a joint research study evaluating the effects of the second generation Contiguous Overlapping Peptides (COP) allergen immunotherapy in a therapeutic model of birch allergy, with the aim of shortening the AIT administration schemes.
GSK Announces Intention to Produce 1 Billion doses of Pandemic Vaccine Adjuvant in 2021
GSK confirmed its intention to manufacture 1 billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted COVID-19 vaccine candidates.